14 citations
,
January 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” A boy's growth and immune problems were caused by a new mutation in the STAT5B gene.
10 citations
,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
5 citations
,
May 2023 in “Frontiers in immunology” Environmental factors like diet and vitamin levels, especially Vitamin D, can affect autoimmune diseases differently, with lifestyle changes potentially improving outcomes.
4 citations
,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
3 citations
,
July 2021 in “International journal of environmental research and public health/International journal of environmental research and public health” Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.
2 citations
,
November 2023 in “Frontiers in microbiology” The health of the gut may be important in developing new ways to prevent, diagnose, and treat alopecia areata.
1 citations
,
January 2014 in “Elsevier eBooks” Melanocytes produce melanin; their defects cause vitiligo and hair graying, with treatments available for vitiligo.
May 2023 in “Sučasna pedìatrìâ. Ukraïna” An 11-year-old child with total hair loss may have a genetic autoimmune disease, and the outlook for hair regrowth is not good.
April 2023 in “Medizinische Genetik” New research has found 14 genes linked to the risk of developing alopecia areata, improving understanding and treatment options.
January 2022 in “Medical research archives” Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.
March 2021 in “Dermatoz” Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.
February 2021 in “Journal of pharmaceutical and biological sciences” No cure exists for alopecia areata, and treatments are personalized.
15 citations
,
December 2018 in “International journal of environmental research and public health/International journal of environmental research and public health” EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.
October 2023 in “Frontiers in Medicine” Dupilumab helped a 4-year-old grow hair back after another treatment failed.
13 citations
,
September 2022 in “Frontiers in immunology” Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
110 citations
,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Alopecia areata is a genetic and immune-related hair loss condition that is often associated with other autoimmune diseases and does not typically cause permanent damage to hair follicles.
40 citations
,
January 2013 in “Dermatologic clinics” More research is needed to understand the genetic causes of Alopecia areata to develop better treatments.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
2 citations
,
October 2022 in “Current Dermatology Reports” People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.
1 citations
,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
1 citations
,
May 2017 in “InTech eBooks” New treatments focusing on immune pathways show promise for stubborn hair loss.
July 2021 in “Journal of dermatology research and therapy” COVID-19 may worsen hair loss, and Nourkrin® could be a safe treatment option, but more research is needed.
489 citations
,
November 2021 in “Signal Transduction and Targeted Therapy” The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
355 citations
,
April 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
36 citations
,
April 2022 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
15 citations
,
December 2021 in “Pharmaceutics” The study found key factors in the cause of hidradenitis suppurativa, its link to other diseases, and identified existing drugs that could potentially treat it.
11 citations
,
January 2022 in “Journal der Deutschen Dermatologischen Gesellschaft” Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.